Eli Lilly and Co (LLY)

81.16
NYSE : Health Care
Prev Close 81.29
Day Low/High 80.77 / 81.46
52 Wk Low/High 67.88 / 88.48
Avg Volume 3.62M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 89.73B
EPS 2.30
P/E Ratio 34.89
Div & Yield 2.04 (2.50%)

Latest News

Eli Lilly Can't Put the Petal to the Metal

Eli Lilly Can't Put the Petal to the Metal

The stock appears to have lost its way.

An Options Play in Eli Lilly

An Options Play in Eli Lilly

I want to use a marriage of stock and ratio call spreads to create a juiced-up, covered-call approach.

Pull Those Stocks Up!

The market is just plain droopy.

Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement

Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement

Allegations that Merck breached patents on diabetes blockbuster Lantus looks like a replay of Sanofi's 2015 case against Eli Lilly.

Will Eli Lilly (LLY) Stock Be Helped by European Drug Recommendation?

Will Eli Lilly (LLY) Stock Be Helped by European Drug Recommendation?

Eli Lilly's (LLY) olaratumab drug for soft tissue sarcoma was recommended for approval by the European Medicines Agency on Friday.

Elanco's Antibiotic Stewardship Plan Yields Innovation, Scientific Advancements

Elanco's Antibiotic Stewardship Plan Yields Innovation, Scientific Advancements

Aggressive 8-point plan to help safeguard animal and human health makes progress, creates pipeline of alternatives to shared-class antibiotics

5 Questions and Answers Take a Measure of Biotech Investor Sentiment

5 Questions and Answers Take a Measure of Biotech Investor Sentiment

How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

I like a bearishly biased, slightly-out-of-the-money vertical put spread.

Eli Lilly (LLY) Stock Higher, Upgraded at JPMorgan

Eli Lilly (LLY) Stock Higher, Upgraded at JPMorgan

Eli Lilly's (LLY) stock rating was lifted to 'overweight' from 'neutral' at JPMorgan on Thursday morning.

Analysts' Actions -- Apple, Lululemon, Nike, Tractor Supply and More

Analysts' Actions -- Apple, Lululemon, Nike, Tractor Supply and More

Here are Thursday's top research calls, including downgrades for Apple, Lululemon Athletica, Nike and Tractor Supply.

Here's Why Investors Should Steer Clear of Opioids

Here's Why Investors Should Steer Clear of Opioids

Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.

Sell These 5 Stocks Now Before They Turn Toxic

Sell These 5 Stocks Now Before They Turn Toxic

It's time to unload these toxic stocks from your portfolio.

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.

Intermediate Level Trade: Eli Lilly

Intermediate Level Trade: Eli Lilly

Consider that the $70 line of support.

Lilly And AstraZeneca Receive FDA Fast Track Designation For AZD3293, An Investigational Treatment For Early Alzheimer's Disease

Lilly And AstraZeneca Receive FDA Fast Track Designation For AZD3293, An Investigational Treatment For Early Alzheimer's Disease

AZD3293 is an oral potent small molecule BACE inhibitor in phase 3 development

Sporting Goods Leveling Field, Which Stocks Say Interest Rates Are Rising: Jim Cramer's Best Blogs

Sporting Goods Leveling Field, Which Stocks Say Interest Rates Are Rising: Jim Cramer's Best Blogs

Jim Cramer ponders how the playing field is being leveled and how three stocks indicate a change in interest rates.

Jim Cramer -- Will Interest Rates Rise? Check These 3 Stocks

Jim Cramer -- Will Interest Rates Rise? Check These 3 Stocks

Johnson & Johnson, American Electric Power and Federal Realty say rates are going higher.

Cramer: 3 Stocks Say Interest Rates Are Going Higher

Cramer: 3 Stocks Say Interest Rates Are Going Higher

Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.

Why Allergan is Fine Without Large M&A

Why Allergan is Fine Without Large M&A

The Dublin-based drugmaker has some 65-plus mid-to-late stage assets in its pipeline.

Elanco Launches New Video Series Illustrating The Powerful Bond Between Service Dogs, Owners

Elanco Launches New Video Series Illustrating The Powerful Bond Between Service Dogs, Owners

Documentary chronicles the journey of two Canine Assistants recipients as they develop unbreakable bonds with their dogs

Are We Sitting Atop Another 8-Year Peak?

Are We Sitting Atop Another 8-Year Peak?

The market action looks very much like it did before the drops that occurred in 2000 and 2008.

Here Is Jim Cramer's Take on Eli Lilly Shares

Here Is Jim Cramer's Take on Eli Lilly Shares

Jim Cramer says Eli Lilly has been overpromising and underdelivering.